Mark Lebwohl, MD, is dean for clinical therapeutics, and chairman emeritus at the Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Case 2 Presentation: 58-Year-Old Woman With GPP
Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.
Delving Into Treatment Options for Patients With Chronic GPP
Experts in dermatology hypothesize about the management of patients with chronic vs acute GPP episodes.
Importance of Determining GPP Event Trigger
Erin Boh, MD, discusses the role of steroid administration and withdrawal as a trigger for GPP, highlighting the importance of physician awareness of external influences initiating this condition.
Benefits of Multidisciplinary Care in the Management of GPP
Experts in dermatology provide insight into the importance of multidisciplinary care in the management of patients with generalized pustular psoriasis (GPP).
Expert Perspectives on Access and Administration of Spesolimab
Erin Boh, MD, shares her opinion on the importance of proactively stocking and streamlining generalized pustular psoriasis (GPP) medication pathways due to emergent care requirements of GPP.
Utility of Spesolimab in the Management of GPP
Mark Lebwohl, MD, discusses the utility of spesolimab, the only FDA-approved treatment for the management of patients with from generalized pustular psoriasis (GPP), highlighting the rapid efficacy of this therapy.
CASE 1 Presentation: 60-year-old African American Woman With GPP
Erin Boh, MD, presents the case of a 60-year-old African American woman with generalized pustular psoriasis (GPP) covering her medical history, initial presentation, potential disease trigger, highlighting important comorbidities of concern and their impact on treatment selection.
New and Promising Drugs in Inflammatory Dermatoses
Mark Lebwohl, MD, discusses his SDPA Annual Summer Dermatology Conference session, "Inflammatory Dermatoses: A Case-Based Review."
FDA Grants Breakthrough Therapy Designation For Spesolimab
The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.
Spesolimab-sbzo Receives a New, Permanent J-code
Mark Lebwohl, MD said it is a step forward for patients diagnosed with generalized pustular psoriasis.
Future of Plaque Psoriasis Management
Drs Mark G. Lebwohl and Alice B. Gottlieb discuss future expectations in the treatment of plaque psoriasis.
Gaps in Plaque Psoriasis Care
Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss gaps in care for the treatment of plaque psoriasis.
Case 2: Patient and Provider Educational Needs
Dr Mark Lebwohl provides insight into the educational needs of both patients and providers surround the utilization of spesolimab and its importance in the management of patients with generalized pustular psoriasis.
Case 2: Changing the Treatment Paradigm
Mark G. Lebwohl, MD, comments on the clinical implications of the recent approval of spesolimab for the treatment of generalized pustular psoriasis.
Case 2: 64-Year-Old Female With a Long History of Plaque Psoriasis
An expert in dermatology presents the case of a 64-year-old female with a long history of plaque psoriasis, focusing on her disease severity and age-related management considerations.
Managing Candidiasis Associated With IL-17 Inhibitors in Plaque Psoriasis
Expert dermatologists discuss the risk of candidiasis with IL-17 inhibitors when managing plaque psoriasis and how to manage candidiasis.
Using Bimekizumab to Manage Plaque Psoriasis
Drs Mark G. Lebwohl and Alice B. Gottlieb discuss the novel mechanism of bimekizumab and how it can change the treatment landscape for plaque psoriasis.
Case 1: Treatment and Disease Management Goals
Goals of generalized pustular psoriasis treatment are reviewed by Dr Mark Lebwohl, where he comments on the need to consider patient disease severity and comorbidities.
Case 1: Treatment and Disease Management Challenges
Dr Mark Lebwohl comments on the treatment and management considerations for a patient suffering from severe generalized pustular psoriasis, highlighting the inefficiency of systemic steroids in the management of this condition.
Case 1: 28-Year-Old Female Patient With Psoriasis
Mark G. Lebwohl, MD, introduces the case of a 28-year-old female nurse with a long history of psoriasis, commenting on her past medical history and initial presentation.
Role of IL-17 Inhibitor Durability in Plaque Psoriasis
Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.
Approaching Plaque Psoriasis Treatment Based on Comorbidities
Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.
Treatment Selection for Plaque Psoriasis
Drs Mark G. Lebwohl and Alice B. Gottlieb discuss how to select treatment for plaque psoriasis based on mechanism of action.
Pathogenesis of Plaque Psoriasis
Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss pathogenesis of plaque psoriasis and new emerging targets.
Psoriasis Case Impressions
Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide impressions to the case and take-home messages for dermatologists and rheumatologists treating psoriasis.
Case Presentation: 45-Year-Old Caucasian Male Diagnosed With Psoriasis
Mark G. Lebwohl, MD, presents a case of a 45-year-old Caucasian male diagnosed with psoriasis.
Biosimilars in Psoriasis
Drs Mark G. Lebwohl and Joseph F. Merola discuss the use of biosimilars in psoriasis and how biosimilars will change the treatment landscape.
Switching Therapies in Psoriasis
Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide insight on when it is appropriate to switch from one biologic to another for a patient with psoriasis.
Role of Anti-TNF Molecules in PsA and PsO Therapy
Expert dermatologists discuss different anti-TNF molecules and the impact of having these types of molecules on psoriasis and psoriatic arthritis care.
Head-to-Head Studies in Psoriasis
Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss different head-to-head studies in psoriasis.
2 Clarke Drive Cranbury, NJ 08512